Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Obesity, pharmacotherapy

St. Peter, John V., and Mehmood A. Khan. Obesity. Pharmacotherapy ... [Pg.109]

Heck AM, Yanovski JA, Calis KA (2000) Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy 20 270-279... [Pg.83]

Aronne LJ, Thornton-Jones ZD. New targets for obesity pharmacotherapy. Clin. Pharmacol. Ther. 2007 81 748-752. [Pg.1029]

There is a high probability of weight regain when obesity pharmacotherapy is discontinued. [Pg.2659]

The debate regarding the appropriateness of obesity pharmacotherapy remains heated, fueled by the recognized national need to treat a growing epidemic, the lack of longterm outcomes studies, and the medical and litigious fallout from the failed use of fen-phen (fenfluramine-phentermine) and dexfenfluramine (Redux). [Pg.2667]

Hofbauer KG, Nicholson JR (2006) Pharmacotherapy of obesity. Exp Clin Endocrinol Diabetes 114 475-484... [Pg.161]

Chiesi M, Huppertz C, Hofbauer KG (2001) Pharmacotherapy of obesity targets and perspectives. Trends Pharmacol Sci 22(5) 247-254... [Pg.161]

Pharmacotherapy, in addition to lifestyle modifications, is reserved for patients with a BMI of 30 kg/m2 or greater or a BMI of 27 kg/m2 or greater with other obesity-related risk factors. Weight likely will be regained if lifestyle changes are not continued indefinitely. [Pg.1529]

Glazer, Gary. Long-term Pharmacotherapy of Obesity 2000 A Review of Efficacy and Safety. Archives of Internal Medicine 161(2001) 1814—1824. [Pg.108]

Keck PE, McElroy SL. Bipolar disorder, obesity, and pharmacotherapy-associated weight gain. J Clin Psychiatry 2003 64(12) 1426-1435. [Pg.94]

Glazer G. Long-term pharmacotherapy of obesity 2000 a review of efficacy and safety. Arch Intern Med 2001 161(15) 1814-1824. [Pg.229]

McDuffie JR, Calls KA, Booth SL, Uwaifo GI, Yanovski JA. Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy 2002 22(7) 814-22. [Pg.477]

Stunkard AJ, Craighead LW, O Brien R. Controlled trial of behaviour therapy, pharmacotherapy, and their combination in the treatment of obesity. Lancet 1980 2 1045-1047. [Pg.433]

Padwal, R., S. K. Li and D. C. Lau (2003). Long-term pharmacotherapy for overweight and obesity a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord 27(12) 1437-46. [Pg.118]

Side-effect profiles of many antiobesity drugs have led to high attrition rates, lessening the overall appeal of pharmacotherapy as a treatment option. In general, anti-obesity drugs should have fairly mild and non-life-threatening side effects, because of the potential off-label use of such compounds for cosmetic purposes in relatively healthy individuals. [Pg.858]

Although not a quantitative measure of renal function, urinary microalbuminuria has been identified as an early marker of renal disease in patients with diabetic nephropathy and numerous other conditions, such as hypertension and obesity. Patients with microalbuminuria (30 to 300 mg/day) on at least two occasions or overt albuminuria (>300 mg/day) should begin to receive pharmacotherapy. For children, microalbuminuria is considered present if albumin excretion exceeds 0.36 mg/kg per day, and overt albuminuria has been defined as an excretion rate that exceeds 4 mg/kg per day. The urinary albumin creatinine ratio is also an accurate predictor of 24-hour proteinuria, a marker of renal disease. Guidelines for monitoring indicate that a urine albumin creatinine ratio of >30 mg/g places the patient at increased risk of developing diabetic nephropathy and is an indication for the initiation of pharmacotherapeutic intervention. Microalbuminuria has also been suggested as a risk factor for renal dysfunction among patients with essential hypertension. ... [Pg.775]

A sufficient degree of obesity (BMI = 30 kg/m and/or WC = 40 inches for males or 35 inches for females, or BMI of 27 to 30 kg/m with concurrent risk factors) should be present before pharmacotherapy-facilitated weight loss is considered. [Pg.2659]

National Task Force on the Prevention and Treatment of Obesity. Longterm pharmacotherapy in the management of obesity. JAMA 1996 276 1907-1915. [Pg.2675]

Bays H, Dujovne C. Pharmacotherapy of obesity currently marketed and upcoming agents. Am J Cardiovasc Drugs 2002 2 245-253. [Pg.159]

Padwal R, Li Sk, Lau DC. Long term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev. 2003 (4) CD004094. [Pg.159]

Finer N. Pharmacotherapy of obesity. Best Pract Res Clin Endocrinol Metab 2002 16 717-742. [Pg.968]

Linne Y, RossnerS. Pharmacotherapy of obesity. Clin Dermatol 2004 22 319-324. [Pg.968]

See other pages where Obesity, pharmacotherapy is mentioned: [Pg.2662]    [Pg.2667]    [Pg.2668]    [Pg.2669]    [Pg.2670]    [Pg.2673]    [Pg.162]    [Pg.2662]    [Pg.2667]    [Pg.2668]    [Pg.2669]    [Pg.2670]    [Pg.2673]    [Pg.162]    [Pg.1533]    [Pg.130]    [Pg.678]    [Pg.3131]    [Pg.114]    [Pg.117]    [Pg.838]    [Pg.842]    [Pg.888]    [Pg.1588]    [Pg.2659]    [Pg.2662]    [Pg.2671]    [Pg.2672]    [Pg.2673]    [Pg.968]    [Pg.414]    [Pg.79]   


SEARCH



Obesity

Pharmacotherapy

© 2024 chempedia.info